Genprex, Inc. develops clinical-stage gene therapies for cancer and diabetes, with recurring updates centered on Reqorsa® Gene Therapy (quaratusugene ozeplasmid) and its diabetes gene therapy candidate Pdx1/MafA, also referred to as GPX-002. Reqorsa uses a non-viral, lipid-based nanoparticle delivery approach for a TUSC2 gene-expressing plasmid and is being developed with approved cancer drugs for non-small cell lung cancer and small cell lung cancer.
Company news commonly covers patent grants and licensed intellectual property for Reqorsa combinations with PD-1 and PD-L1 antibodies, biomarker research involving TROP2 and PTEN, preclinical and clinical data presentations, sponsored research with UT MD Anderson, oncology trial references such as Acclaim-1 and Acclaim-3, diabetes preclinical research, industry conference participation and Nasdaq compliance updates.
Genprex announced the first patient dosing in its Phase 1 Acclaim-3 clinical study of Reqorsa Immunogene Therapy in combination with Tecentriq to treat extensive-stage small cell lung cancer (ES-SCLC). This trial, which aims to determine the maximum tolerated dose for a Phase 2 expansion expected in the second half of 2024, is supported by FDA Orphan Drug and Fast Track designations. Genprex highlighted the poor prognosis of ES-SCLC and the benefits of current treatments, emphasizing the potential of their therapy. Positive outcomes from the Phase 1 Acclaim-1 study in non-small cell lung cancer have enabled an accelerated timeline for Acclaim-3.
Genprex, a clinical-stage gene therapy company, announced the appointment of Jose A. Moreno Toscano as Chairman of the Board following the passing of the previous Chairman, Rodney Varner. Mr. Moreno Toscano brings over 20 years of experience in the pharmaceutical and biotechnology industries, focusing on revenue growth, market expansion, and organizational development.
Genprex, a clinical-stage gene therapy company, announced the passing of its co-founder and CEO, Rodney Varner, due to complications from cancer. Ryan Confer has been appointed as the new President and CEO. Under Varner's leadership, the company achieved significant milestones in developing therapies for cancer and diabetes. The company expresses its condolences to Varner's family and colleagues.
Genprex, Inc. (
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.